Key result
A review of 23 heart failure registries (enrolling 1,037 to 25,000 patients) highlights their role in providing real-world epidemiological data to complement randomized clinical trials.
Answers are grounded in this paper and cite their sources.
Heart failure registries are essential tools that complement clinical trials by providing real-world epidemiological data, identifying gaps in guideline implementation, and highlighting regional disparities in care.
This article refers to ‘European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions’ by Maria G. Crespo-Leiro et al. published in this issue on pages 613–625. Heart failure (HF) registries have developed into powerful survey tools providing valuable epidemiological data and contributing crucially to our understanding of this syndrome.1 A recent study identified 23 registries (43% multinational and 57% national) reporting data for HF patients.2 Those registries concerned acute HF (31%), chronic HF (43%), and both acute and chronic HF (26%). The number of patients included varied from 1037 to 25 000 and the average follow-up ranged from 3 months to 53 months. The accumulated evidence concerned patient demographics (in 100% of registries), co-morbidities (87%), diagnosis and disease classification (78%), mortality (78%), hospitalization (96%), prescribed drugs (100%), and patient-reported outcomes (17%). Registries typically enrol unselected subjects suffering from a specific medical condition and thus provide a picture closer to the real world compared with clinical trials. Clinical trials, in contrast, are usually designed to sample from a carefully selected subpopulation within the medical condition, with particular characteristics that ensure the internal validity of the trial at the expense of the external validity and representation. In addition, instead of guiding therapy, as in the case of clinical trials studying a specific therapeutic intervention, registries depict the current method of management, hence identifying problems in physician adherence to recommendations and in patient compliance with instructions and thus drawbacks in medical training, patient education, and health-care organization. Registries typically represent an epidemiological snapshot of the population under study. For example, in the case of acute HF, they provide baseline demographic and clinical features at the time of hospital admission along with medical history, previous events, and medications. In addition, registries of hospitalized patients also provide information on applied therapies during hospitalization, length of hospital stay and in-hospital outcomes. However, few registries for HF have provided long-term follow-up data. The European Heart Failure Survey I and the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) provided evidence on mortality and hospital readmission for up to 90 days post-discharge.3, 4 Another two HF registries, the Indian Trivandrum Heart Failure Registry and the Sub-Saharan Africa Survey of Heart Failure (THESUS-HF) provided patient outcome at 90 days and 180 days post-discharge, respectively.5, 6 More importantly, the Acute Decompensated Heart Failure National Registry (ADHERE) provided outcome information for up to 1 year after discharge.7 This is also the case for the two latest HF registries of the EURObservational Research Programme of the European Society of Cardiology (ESC), the previously published ESC HF Pilot Survey and the ESC HF Long-Term Registry (ESC-HF-LT-R) that is published in the current issue of this Journal.8, 9 The importance of long-term prospective outcome data lies in the fact that it allows the evaluation of the prognostic impact of patient features, such as demographics, clinical characteristics, laboratory measurement, and comorbid conditions. In this regard, a number of comorbid conditions have lately been recognized as independent determinants of prognosis in HF, a finding that stresses the importance of their timely diagnosis and management. The documentation of prognostic features is crucial for the identification of therapeutic requirements and treatment targets with the potential to improve patient outcomes in terms of mortality, morbidity, and hospitalization—a particularly unmet need in the case of acute HF.10 Long-term prospective data may also provide indirect information on the effect of applied therapies, although this latter piece of evidence should be derived from properly designed, ideally randomized, clinical trials. Heart failure is characterized by marked regional and ethnic differences. This heterogeneity has an impact upon the care provided and thus patient outcome, a fact that stresses the need for harmonization of HF management.8, 11 Those differences result from a number of reasons, including financial, organizational, educational, and even cultural ones.11 Therefore, representation of different geographical regions, countries and ethnicities is crucial to determine the actual requirements in health-care delivery, in terms of distribution of medical resources, implementation of therapeutic recommendations, organization of health-care systems and education of health-care professionals and patients. In this regard, the ESC-HF-LT-R9 created a large network of centres and countries across the region served by the ESC and thus was able to document significant regional disparities in terms of the severity of HF, applied therapies, and 1-year outcome. In addition to regional and ethnic differences, age-related heterogeneity also exists. Elderly patients, in particular, are characterized by different epidemiology, mode of presentation, prognostic indicators and thus therapeutic requirements, as well as management inequalities, and those differences should also be reflected by registries.12 The management of HF changes over time. There has been a increase in the use of disease-modifying therapies to improve patient outcome, as indicated by the differences in the use of neurohormonal inhibitors and in-hospital mortality between the Acute Heart Failure Global Registry of Standard Treatment (ALARM-HF) conducted in 2006–2007 and the ESC-HF Pilot survey conducted in 2009–2010.13 Registries should therefore reflect the temporal trends in HF management and provide updated evidence. In addition to improvement in the implementation of recommendations, the change in clinical practice resulting from novel evidence provided by clinical trials also imposes a temporal update of HF evidence provided by the registries. In addition to the medical and social burden, HF also imposes an enormous financial burden that currently represents 2% of total health-care expenditure and is expected to rise by almost 120% in 2030 in the USA.14 The vast majority of HF-related expenditure results from hospitalizations, with the direct mean cost of a single HF admission in Europe being €3200.15 Therefore, reduction in HF-related cost represents another important unmet need and, in this context, registries should be able to provide the data that are required for cost analyses. There should be a continuous crosstalk between clinical trials and registries (Figure 1). Registries indicate unmet therapeutic requirements and gaps in evidence that need to be addressed by clinical trials. Conversely, clinical trials provide the evidence to change the clinical practice, which in turn indicates new pieces of evidence that should be recorded and investigated by the registries. As a result, an appropriately designed registry should on one hand shed new light on unmet therapeutic and health-care needs to help design trials and update health-care policies and on the other be updated to reflect the change in practice indicated by novel evidence. The change in clinical practice creates the need for acquiring novel information. For example, patients treated with the novel neurohormonal inhibitors, the angiotensin receptor and neprilysin inhibitors (ARNi), cannot be followed by measuring the B-type natriuretic peptide (BNP) plasma levels, as BNP is upregulated by the therapy itself and therefore its fluctuations do not reflect accurately the severity of the syndrome. The current requirements for HF registries, as outlined above, include the ability to provide long-term prospective updated evidence that may also be used for cost analyses, proper representation of HF populations, and constant interactions with clinical trials (Table 1). The ESC-HF-LT-R was an important step forward.9 The recently launched International Registry to Assess Medical Practice with Longitudinal Observation for Treatment of Heart Failure (REPORT-HF) bears many of the aforementioned quality features.16 It is a global prospective survey that will enrol 20 000 hospitalized HF patients in 300 sites located in 40 countries, designed to provide long-term outcome data for up to 3 years, hence allowing characterization of longitudinal patient trajectories, while also recording data on quality of life, resource utilization, and healthcare costs. It seems that a continuously running prospective representative registry with the flexibility to adapt to the evolution of clinical practice and with periodic reporting would be an invaluable tool to improve the quality of care provided, patient outcomes, and the overall socioeconomic burden of the HF syndrome.
No takes yet. Share an insight, caveat, or question.
Parissis et al. (2016) conducted an editorial in Heart failure. A review of 23 heart failure registries (enrolling 1,037 to 25,000 patients) highlights their role in providing real-world epidemiological data to complement randomized clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: